Table 1 Participant characteristics

From: Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116

 

Group 1

Group 2

Group 3

 

V116 (n = 1918)

PCV20 (n = 1177)

PPSV23 (n = 741)

V116 (n = 485)

V116 prior PCV13 (n = 229)

V116 prior PPSV23 (n = 174)

V116 other prior vax (n = 105)

Sex (n (%))

 - Male

824 (43.0)

507 (43.1)

331 (44.7)

269 (55.5)

112 (48.9)

74 (42.5)

50 (47.6)

 - Female

1094 (57.0)

670 (56.9)

410 (55.3)

216 (44.5)

117 (51.1)

100 (57.5)

55 (52.4)

Age in years (n (%))

 − 18 to 49

0 (0.0)

0 (0.0)

0 (0.0)

199 (41.0)

0 (0.0)

0 (0.0)

0 (0.0)

 − 50 to 64

931 (48.5)

587 (49.9)

342 (46.2)

286 (59.0)

48 (21.0)

80 (46.0)

17 (16.2)

 - ≥65

987 (51.5)

590 (50.1)

399 (53.8)

0 (0.0)

181 (79.0)

94 (54.0)

88 (83.8)

 - Mean

63.9

63.9

63.7

49.9

68.7

65.5

71.0

Risk conditions* (n (%))

 - Human immunodeficiency virus

0 (0.0)

0 (0.0)

0 (0.0)

99 (20.4)

0 (0.0)

0 (0.0)

0 (0.0)

 - Alcoholism

6 (0.3)

3 (0.3)

0 (0.0)

7 (1.4)

1 (0.4)

0 (0.0)

0 (0.0)

 - Chronic heart disease

41 (2.1)

16 (1.4)

14 (1.9)

87 (17.9)

7 (3.1)

4 (2.3)

2 (1.9)

 - Chronic kidney disease

36 (1.9)

22 (1.9)

12 (1.6)

42 (8.7)

8 (3.5)

4 (2.3)

6 (5.7)

 - Chronic liver disease

34 (1.8)

22 (1.9)

21 (2.8)

37 (7.6)

12 (5.2)

15 (8.6)

3 (2.9)

 - Chronic lung disease

186 (9.7)

131 (11.1)

49 (6.6)

94 (19.4)

31 (13.5)

19 (10.9)

17 (16.2)

 - Diabetes mellitus

299 (15.6)

182 (15.5)

89 (12.0)

204 (42.1)

62 (27.1)

37 (21.3)

28 (26.7)

 - Smoking

198 (10.3)

133 (11.3)

73 (9.9)

109 (22.5)

18 (7.9)

13 (7.5)

8 (7.6)

 - Any condition (one or more)

648 (33.8)

409 (34.7)

218 (29.4)

485 (100.0)

101 (44.1)

73 (42.0)

48 (45.7)

  1. *Participants may have more than one risk condition